1. Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate;Poggio;Ann Oncol,2022
2. Neoadjuvant chemotherapy in early triple-negative breast cancer: a pairwise and network meta-analysis of pathological complete response;Weng;Inq J Health Care Organ Provis Financ,2021
3. Platinum and taxane based adjuvant and neoadjuvant chemotherapy in early triple-negative breast cancer: a narrative review;Tian;Front Pharmacol,2021
4. A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer;Yan;Ther Adv Med Oncol,2022
5. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial;Lv;Lancet Oncol,2021